晶泰控股-P(02228)今日盘中大涨6.26%,引发市场广泛关注。主要原因是消息面上,晶泰控股-P下属Ailux Biologics与跨国制药企业优时比(UCB)签署大分子药物发现AI平台授权协议。
根据协议内容,晶泰科技商业授权优时比使用其自主研发的XtalFold AI平台进行大分子药物发现和工程化设计。XtalFold平台可以基于人工智能算法对生物大分子的结构进行高精度建模,为大分子药物研发提供关键结构信息,在多个研发阶段加速创新。业内评测显示,XtalFold在整体建模成功率和困难区域(如抗体-抗原界面)的质量方面表现领先。
此次授权协议有助于晶泰控股-P进一步发挥人工智能在生物医药研发领域的优势,为其未来业绩增长注入新动力。市场对该公司长期发展前景的信心进一步增强,从而推动股价在盘中出现较大涨幅。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.